Somatostatin Analogs Market Report 2025

The somatostatin analogs market size has grown strongly in recent years. It will grow from $6.73 billion in 2024 to $7.18 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increased net incidence, advancements in oncology research, clinical efficacy in symptom management, expansion of indications, patient preference for long-acting formulations.

The somatostatin analogs market size is expected to see strong growth in the next few years. It will grow to $9.48 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to continued rise in net incidence, research focus on rare diseases, development of combination therapies, advancements in personalized medicine, global health initiatives in cancer care. Major trends in the forecast period include global aging population, healthcare infrastructure development in emerging markets, strategic collaborations and partnerships, pricing pressures and reimbursement challenges, technological integration in healthcare.

The somatostatin analogs market is expected to experience significant growth due to the increasing incidence of neuroendocrine tumors. Neuroendocrine tumors, originating in specialized neuroendocrine cells, can lead to excessive hormone production. Somatostatin analogs play a crucial role in regulating hormone levels, inhibiting tumor growth, and alleviating symptoms associated with carcinoid disease. For instance, in 2022, Cancer Australia reported approximately 5,437 new cases of neuroendocrine tumors in Australia, highlighting the prevalence of this condition. The rise in neuroendocrine tumor incidence is a key factor driving the expansion of the somatostatin analogs market.

The growth of the somatostatin analogs market is expected to be propelled by the increasing aging population. The demographic shift toward a higher proportion of individuals aged 65 and older is associated with a higher incidence of diseases that necessitate the use of somatostatin analogs. As of 2022, there were 771 million people aged 65 and above globally, constituting nearly 10% of the world's population, as reported by Visual Capitalist. This demographic trend contributes to a growing demand for pharmaceuticals, including somatostatin analogs, as they are commonly used in conditions prevalent among the elderly. Consequently, the expanding aging population is a significant driver for the growth of the somatostatin analogs market.

Major companies in the somatostatin analogs market are focused on developing advanced products, such as targeted radiopharmaceuticals, to improve the precision and effectiveness of cancer treatments, particularly for patients with somatostatin receptor-positive tumors. Targeted radiopharmaceuticals are specialized drugs that combine radiation-emitting isotopes with molecules designed to specifically bind to cancer cells, enabling precise delivery of therapeutic radiation to tumor sites while reducing exposure to surrounding healthy tissues. For example, in January 2024, Lantheus, a US-based company specializing in radiopharmaceuticals, launched Lutetium Lu-177 Dotatate. This radiolabeled somatostatin analog is used in peptide receptor radionuclide therapy (PRRT) for treating advanced somatostatin receptor-positive neuroendocrine tumors. Clinical studies have shown that it significantly improves progression-free survival and response rates compared to traditional somatostatin analogs like octreotide, making it a crucial option for patients whose disease has progressed despite previous treatments. Its targeted approach allows for effective tumor control while minimizing systemic exposure, enhancing the overall therapeutic profile for managing neuroendocrine malignancies.

Major companies in the somatostatin analogs market are concentrating on developing advanced products, such as oral selective agonists, to enhance patient compliance and improve the treatment of conditions linked to excess growth hormone, like acromegaly. Oral selective agonists are compounds designed to selectively activate specific receptors in the body when taken orally, resulting in targeted biological responses while minimizing effects on other receptor types. For instance, in September 2024, Crinetics Pharmaceuticals Inc., a US-based company focused on discovering and developing novel therapeutics for rare endocrine diseases and endocrine-related tumors, submitted a new drug application for paltusotine to treat acromegaly. Paltusotine is an oral, nonpeptide small-molecule agonist specifically targeting somatostatin receptor type 2 (SST2). This innovative drug offers a once-daily dosing regimen, improving patient compliance compared to traditional injectable somatostatin analogs like octreotide and lanreotide. Clinical studies have demonstrated that paltusotine effectively lowers insulin-like growth factor I (IGF-I) levels, presenting a promising alternative for patients needing long-term management of hormone hypersecretion.

In October 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, partnered with Philogen S.p.A. to enhance its portfolio and broaden access to innovative cancer treatments. This collaboration aims to commercialize the under-development skin cancer drug Nidlegy in Europe, Australia, and New Zealand. Philogen S.p.A. is an Italy-based biotechnology company dedicated to developing targeted therapeutics for oncology.

Major companies operating in the somatostatin analogs market include Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer Aktiengesellschaft, Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Viatris Inc., AstraZeneca plc, Johnson & Johnson, Genentech Inc., OctreoPharm Sciences GmbH.

North America was the largest region in the global somatostatin analogs treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the somatostatin analogs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the somatostatin analogs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A somatostatin analog is a man-made version of somatostatin, a natural hormone that regulates the production of various hormones in the body, such as serotonin and growth hormone. The primary purpose of somatostatin analogs is to slow down the release of these hormones. These analogs are particularly employed to alleviate symptoms associated with carcinoid syndrome, which may include diarrhea and skin flushing.

The key somatostatin analogs in medical use are octreotide, lanreotide, and pasireotide. Octreotide is a medication designed to mimic the effects of somatostatin by blocking the release of growth hormones. It is commonly utilized in the treatment of specific conditions such as tumor-related diarrhea and flushing. These somatostatin analogs find applications in addressing various medical conditions, including acromegaly, Cushing's syndrome, neuroendocrine tumors, carcinoid syndrome, and others. The end users for these analogs include hospitals and pharmaceutical companies, emphasizing their significance in medical treatments and therapies.

The somatostatin analogs market research report is one of a series of new reports that provides somatostatin analogs market statistics, including the somatostatin analogs industry global market size, regional shares, competitors with a somatostatin analogs market share, detailed somatostatin analogs market segments, market trends, and opportunities, and any further data you may need to thrive in the somatostatin analogs industry. This somatostatin analogs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The somatostatin analogs market consists of sales of sandostatin, sandostatin lar, olatuton, somatuline LA, and somatuline autogel. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.